Their product development strategy is in full swin
Post# of 30067
Posted On: 11/11/2014 10:42:20 AM
Their product development strategy is in full swing and they are hitting on their stated objectives one by one. I am more convinced then ever that they are going to spin out the diagnostic division, once uplisted of course. The diagnostic division at that point in time will consist of LymPro, NuroPro, I assume BC SeraPro, and most likely a new complementary late-stage neurology-focused diagnostic asset.
Quote:
SUNNYVALE, Calif.--(BUSINESS WIRE)-- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today (April 04, 2013) announced it will adopt a holding company structure with separate business units in order to more effectively develop its various assets. Reflecting the change in structure, the corporation will change its name to Amarantus Bioscience Holdings, Inc.
Initially, the Company will form two business units: Amarantus Therapeutics, centered on its patented therapeutic protein Mesencephalic Astrocyte Neurotrophic Factor (MANF), and Amarantus Diagnostics, focused on developing the LymPro Blood Test for Alzheimer’s disease and the NuroPro Blood Test for Parkinson’s disease. Currently, MANF is in preclinical testing as a potentially disease-modifying treatment for Parkinson’s disease, and the two diagnostic tests are being prepared for Phase 2 studies. The Company will also evaluate the acquisition/in-licensure of clinical-stage drug candidate to complement MANF within the Amarantus Therapeutics subsidiary (ELTO), and may evaluate additional strategic significantly undervalued opportunities over time using its deep industry knowledge and connections. (P16, the "new" diagnostic acquisition that is expected)
“While our near-term development objectives remain the same, the new structure will allow us to allocate capital more efficiently, and form management teams specific to each business or product line (Keywood, Segal, Clark, Grimes, Jorgenson, Wakefield) ,” said Gerald E. Commissiong, President and Chief Executive Officer of Amarantus BioScience. “We will also be able to create new business units to leverage other assets we already own, such as our PhenoGuard Protein Discovery platform, (PhenoGuard was listed as a new division in a recent presentation) or that we may acquire. Additionally, we have decided not to spinoff Amarantus Diagnostics at this time, and will re-evaluate the potential spinoff of various business units as the situation with each entity unfolds.”
Quote:
As the launch of LymPro nears, the company is also looking to maximize the value of the investment we have made in the asset since acquiring it in late 2012. As a holding company, Amarantus is continuing to evaluate methods of returning value to shareholders, including a potential spinoff of the company’s diagnostic division. In addition to LymPro and our NuroPro Parkinson’s diagnostic, we are actively evaluating additional complementary late-stage neurology-focused diagnostic assets that would bolster our diagnostic division and make for a successful ‘spin-out’ while concurrently returning value to our shareholders. We believe we will be able to execute on this strategy in the near-term.
(0)
(0)